Aperture Investors’s BioNTech BNTX Stock Holding History

Aperture Investors’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-18,386	Closed	-$4.12M	–	84
2021 Q2	$4.12M	Buy	+18,386	New	+$3.47M	0.47%	55

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Aperture Investors's BNTX Position: Q3 2021 in Review

Aperture Investors sold out of BioNTech (BNTX) in Q3 2021, closing a stake of 18,386 shares — an estimated $4.12M sold.

Aperture Investors first reported a position in BNTX in Q2 2021 and held it in 1 quarter. The position peaked at $4.12M in Q2 2021. 335 funds tracked by Wall St. Rank hold BNTX as of Q3 2021.

Aperture Investors reported no remaining BioNTech position as of Q3 2021 after selling out during the quarter.
Aperture Investors sold 18,386 BioNTech shares in Q3 2021, an estimated $4.12M.
Aperture Investors first reported a position in BioNTech in Q2 2021 and held it in 1 quarter.
Aperture Investors's BioNTech position peaked at $4.12M in Q2 2021.
335 funds tracked by Wall St. Rank held BioNTech as of Q3 2021.

Based on Aperture Investors's 13F filing for Q3 2021, filed 15 Nov 2021.